New Enterprise Associates

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Nodar, Inc. is a technology company based in Boston, Massachusetts, specializing in advanced sensor systems for various transportation modes, including cars, trucks, drones, ships, trains, and aircraft. Founded in 2018, Nodar develops innovative camera-based 3D vision systems, notably the Nodar Longbow and Hammerhead products. These systems utilize off-the-shelf cameras to provide long-range, high-precision depth sensing, making them suitable for Level 3 and Level 4 autonomous vehicle applications. Their technology is designed to enhance safety and performance in vehicles by enabling features such as collision warning, path planning, automatic emergency braking, and parking assistance. Nodar aims to deliver reliable and cost-effective sensor solutions that meet the evolving demands of the automotive, marine, and railway industries.

Proof of Learn is a Boston-based company founded in 2021 that serves as a talent marketplace for emerging developers by focusing on education, upskilling, and job placement. It operates Metacrafters.io, a multichain learn-to-earn platform designed to teach users how to write smart contracts and build on-chain applications. By leveraging blockchain technology, Proof of Learn aims to provide equal access to education and next-generation job opportunities globally. Its innovative approach enables learners to acquire skills, earn rewards, and secure employment in the evolving Web3 landscape.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Tulip Interfaces, Inc. is a technology company specializing in the development of shop floor applications for the manufacturing industry. Founded in 2012 and based in Somerville, Massachusetts, Tulip provides a no-code platform that enables companies to enhance productivity, quality, and operational efficiency. Its applications integrate data from sensors and connect existing shop floor equipment, allowing for real-time visualization of relevant information. Tulip's platform is designed for various industries, including consumer electronics, pharmaceuticals, apparel, aerospace, automotive, and medical devices. By empowering frontline workers with intuitive software and hardware tools, Tulip facilitates digital transformation in manufacturing, helping organizations address critical challenges and improve their operations through enhanced visibility and traceability.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Burrow, Inc. is a New York-based company that designs, manufactures, and supplies luxury furniture for residential use. Founded in 2016, Burrow specializes in creating easy-to-move and customizable seating options such as sofas, sectionals, loveseats, and armchairs, as well as tables, rugs, and various accessories. The furniture is crafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow aims to provide customers with comfortable and stylish furnishing alternatives while avoiding traditional retail markups. The company operates showrooms in several states, including Washington, Massachusetts, Texas, and California, and also sells its products online. Additionally, Burrow has a manufacturing facility located in Mexico City, Mexico.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Akouos, Inc. is a biotechnology company dedicated to developing precision genetic medicine aimed at restoring, improving, and preserving hearing for individuals with various forms of hearing loss. Utilizing a proprietary adeno-associated viral vector library and an innovative delivery approach, Akouos focuses on gene therapies tailored to genetically-defined patient populations, including those affected by specific genetic mutations, ototoxic drug exposure, and age-related hearing loss. The company's lead product candidate, AK-OTOF, targets hearing loss associated with mutations in the OTOF gene. Founded in 2016 and based in Boston, Massachusetts, Akouos collaborates with strategic partners, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing effective treatments for sensorineural hearing loss.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Burrow, Inc. is a New York-based company that designs, manufactures, and supplies luxury furniture for residential use. Founded in 2016, Burrow specializes in creating easy-to-move and customizable seating options such as sofas, sectionals, loveseats, and armchairs, as well as tables, rugs, and various accessories. The furniture is crafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow aims to provide customers with comfortable and stylish furnishing alternatives while avoiding traditional retail markups. The company operates showrooms in several states, including Washington, Massachusetts, Texas, and California, and also sells its products online. Additionally, Burrow has a manufacturing facility located in Mexico City, Mexico.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Tulip Interfaces, Inc. is a technology company specializing in the development of shop floor applications for the manufacturing industry. Founded in 2012 and based in Somerville, Massachusetts, Tulip provides a no-code platform that enables companies to enhance productivity, quality, and operational efficiency. Its applications integrate data from sensors and connect existing shop floor equipment, allowing for real-time visualization of relevant information. Tulip's platform is designed for various industries, including consumer electronics, pharmaceuticals, apparel, aerospace, automotive, and medical devices. By empowering frontline workers with intuitive software and hardware tools, Tulip facilitates digital transformation in manufacturing, helping organizations address critical challenges and improve their operations through enhanced visibility and traceability.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Tiburio Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, specializes in developing and manufacturing medicines for rare endocrine diseases and tumors related to the endocrine system. The company's primary focus is on TBR-760, a drug candidate designed to treat non-functioning pituitary adenoma (NFPA) using a dopamine-somatostatin chimeric molecule aimed at shrinking or halting tumor growth. Additionally, Tiburio explores other compounds like TBR-065 for treating rare endocrine diseases where effective treatments are limited.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Akouos, Inc. is a biotechnology company dedicated to developing precision genetic medicine aimed at restoring, improving, and preserving hearing for individuals with various forms of hearing loss. Utilizing a proprietary adeno-associated viral vector library and an innovative delivery approach, Akouos focuses on gene therapies tailored to genetically-defined patient populations, including those affected by specific genetic mutations, ototoxic drug exposure, and age-related hearing loss. The company's lead product candidate, AK-OTOF, targets hearing loss associated with mutations in the OTOF gene. Founded in 2016 and based in Boston, Massachusetts, Akouos collaborates with strategic partners, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing effective treatments for sensorineural hearing loss.

Formlabs Inc. is a company that designs and manufactures advanced 3D printing systems targeted at engineers, designers, and artists. Established in 2011 and headquartered in Somerville, Massachusetts, Formlabs offers a diverse range of products, including the Form 3, Form 3B, and Form 3L printers, all utilizing Low Force Stereolithography (LFS) technology. The company also provides post-processing solutions such as Form Wash and Form Cure, as well as the Fuse 1 SLS 3D printer and the Form Cell manufacturing solution. Formlabs develops high-performance materials for various applications in industries like dental, healthcare, jewelry, and education. Its PreForm software facilitates the preparation of models for printing, making it a preferred choice among professionals worldwide. With additional offices in Germany, Japan, China, Singapore, Hungary, and North Carolina, Formlabs continues to innovate in the field of 3D printing, enhancing the capabilities of digital fabrication.

Tamr, Inc. is an enterprise data unification company that specializes in developing solutions for data integration and management. Founded in 2013 by industry veterans, the company offers a platform that combines machine learning with human insight to effectively identify and connect diverse internal and external data sources. This technology allows organizations to curate siloed data at scale, generating valuable insights for various business applications. Tamr's offerings include enterprise data preparation software, clinical data conversion, procurement optimization, and customer data integration, catering to industries such as financial services, life sciences, government, and telecommunications. With its headquarters in Cambridge, Massachusetts, Tamr also maintains offices in major U.S. cities and London, reflecting its commitment to delivering innovative data solutions to a broad range of clients.

Automation Anywhere, Inc. is a global leader in Robotic Process Automation (RPA), specializing in the development of AI-powered software solutions designed to enhance business efficiency. Founded in 2003 and headquartered in San Jose, California, the company offers a cloud-native platform that integrates RPA with artificial intelligence, machine learning, and analytics. Its flagship products include Automation Anywhere Enterprise, which automates IT and business processes; Automation Anywhere Server for streamlined business operations; and IQ Bot, a cognitive automation solution that addresses complex business tasks. Additionally, the company provides a comprehensive suite of testing tools, such as Testing Anywhere, which supports quality assurance across various platforms. Automation Anywhere also offers consulting services and collaborates strategically with Microsoft Azure. The company has expanded its presence internationally with offices in several major cities across the United States, Europe, the Middle East, and Asia.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Burrow, Inc. is a New York-based company that designs, manufactures, and supplies luxury furniture for residential use. Founded in 2016, Burrow specializes in creating easy-to-move and customizable seating options such as sofas, sectionals, loveseats, and armchairs, as well as tables, rugs, and various accessories. The furniture is crafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow aims to provide customers with comfortable and stylish furnishing alternatives while avoiding traditional retail markups. The company operates showrooms in several states, including Washington, Massachusetts, Texas, and California, and also sells its products online. Additionally, Burrow has a manufacturing facility located in Mexico City, Mexico.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing novel, non-opioid, and non-addictive therapies for chronic pain management. Founded in 2013, the company focuses on addressing significant unmet medical needs in this area. Its product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, as well as Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain linked to inflammatory and neuropathic conditions. Other candidates include CNTX-6970, also in Phase I for inflammatory pain, and CNTX-2022, a high-concentration topical lidocaine gel in Phase I for various pain types. CNTX-6016 is in pre-clinical stages for chronic neuropathic pain. Centrexion aims to provide patients with safe and effective pain relief options through innovative treatment modalities.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Akouos, Inc. is a biotechnology company dedicated to developing precision genetic medicine aimed at restoring, improving, and preserving hearing for individuals with various forms of hearing loss. Utilizing a proprietary adeno-associated viral vector library and an innovative delivery approach, Akouos focuses on gene therapies tailored to genetically-defined patient populations, including those affected by specific genetic mutations, ototoxic drug exposure, and age-related hearing loss. The company's lead product candidate, AK-OTOF, targets hearing loss associated with mutations in the OTOF gene. Founded in 2016 and based in Boston, Massachusetts, Akouos collaborates with strategic partners, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing effective treatments for sensorineural hearing loss.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Tulip Interfaces, Inc. is a technology company specializing in the development of shop floor applications for the manufacturing industry. Founded in 2012 and based in Somerville, Massachusetts, Tulip provides a no-code platform that enables companies to enhance productivity, quality, and operational efficiency. Its applications integrate data from sensors and connect existing shop floor equipment, allowing for real-time visualization of relevant information. Tulip's platform is designed for various industries, including consumer electronics, pharmaceuticals, apparel, aerospace, automotive, and medical devices. By empowering frontline workers with intuitive software and hardware tools, Tulip facilitates digital transformation in manufacturing, helping organizations address critical challenges and improve their operations through enhanced visibility and traceability.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

ClearMotion, Inc. is an automotive technology company that specializes in developing advanced suspension systems to enhance vehicle comfort and handling. Founded out of MIT in 2008 and based in Billerica, Massachusetts, with operations in Nuneaton, United Kingdom, ClearMotion integrates hardware and software to create a proactive ride system that anticipates and counteracts shocks and vibrations from uneven road surfaces. This innovative technology not only improves ride quality but also enhances the overall user experience in vehicles. By mapping road surfaces in real-time, ClearMotion's system can mitigate the effects of road roughness almost instantaneously, ensuring a smoother ride for both drivers and passengers.

Docent Health is a company based in Cambridge, Massachusetts, that specializes in developing software and mobile applications aimed at enhancing patient care and engagement for health systems. Its enterprise consumer engagement platform integrates digital and human interactions to provide personalized support for patients, guiding them according to their specific needs and preferences. By utilizing intelligent, real-time text messaging, Docent Health focuses on fostering lasting patient relationships and improving customer experiences. The company's approach combines insights from various industries, including retail and hospitality, to deliver customer-centric care that enhances patient satisfaction, increases customer lifetime value, and helps health systems grow their market share.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Docent Health is a company based in Cambridge, Massachusetts, that specializes in developing software and mobile applications aimed at enhancing patient care and engagement for health systems. Its enterprise consumer engagement platform integrates digital and human interactions to provide personalized support for patients, guiding them according to their specific needs and preferences. By utilizing intelligent, real-time text messaging, Docent Health focuses on fostering lasting patient relationships and improving customer experiences. The company's approach combines insights from various industries, including retail and hospitality, to deliver customer-centric care that enhances patient satisfaction, increases customer lifetime value, and helps health systems grow their market share.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

Glamsquad, Inc., also known as GLAM Group, is a New York-based company that specializes in providing on-demand beauty services. Founded in 2013, Glamsquad offers a range of services including hair styling, makeup application, and nail care, catering to clients in major cities such as New York City, Los Angeles, Miami, Washington, D.C., Boston, and the San Francisco Bay Area. The company employs a network of trained and vetted beauty professionals who deliver personalized experiences for various occasions, including home appointments, parties, and weddings. Glamsquad leverages technology to facilitate easy booking through its app and website, ensuring clients can select services, schedule appointments, and enjoy the convenience of professional beauty care at home. In addition to services, Glamsquad has introduced its own line of hair and makeup products, designed to complement their offerings and meet client needs.

Acquia Inc., established in 2007, is a technology company based in Boston, Massachusetts, with an additional office in Pune, India. It specializes in developing and operating a cloud-based platform that empowers organizations to create, manage, and optimize digital experiences. Acquia's platform offers a range of solutions, including commerce, content, community, and contextual services, catering to diverse industries such as government, consumer brands, higher education, and more. Key products include Acquia Cloud, a Platform-as-a-Service for Drupal website creation and management; Acquia Lift for site templating; Acquia Content Hub for multi-channel content distribution; and Acquia Journey for data-driven customer journey creation. Acquia also provides web content management, security, commerce solutions, and technical support services. The company's platform enables organizations to accelerate time to market, enhance customer engagement, and deliver contextually relevant digital experiences across various channels.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics for diseases linked to the excessive activation of the complement system. Utilizing a peptide chemistry platform, the company produces synthetic macrocyclic peptides that offer the specificity and diversity of antibodies alongside the pharmacological advantages of small molecules. Its lead product candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, as well as a Phase Ib trial for patients with renal impairment. In addition to Zilucoplan, Ra Pharmaceuticals is advancing pre-clinical programs targeting Factor D inhibition for C3 glomerulonephritis and dense deposit disease, among other conditions. The company has also established a collaboration with Merck & Co., Inc. to explore orally available cyclic peptides for cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.

Tamr, Inc. is an enterprise data unification company that specializes in developing solutions for data integration and management. Founded in 2013 by industry veterans, the company offers a platform that combines machine learning with human insight to effectively identify and connect diverse internal and external data sources. This technology allows organizations to curate siloed data at scale, generating valuable insights for various business applications. Tamr's offerings include enterprise data preparation software, clinical data conversion, procurement optimization, and customer data integration, catering to industries such as financial services, life sciences, government, and telecommunications. With its headquarters in Cambridge, Massachusetts, Tamr also maintains offices in major U.S. cities and London, reflecting its commitment to delivering innovative data solutions to a broad range of clients.

XTuit Pharmaceuticals, Inc., established in 2011 and headquartered in Waltham, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. The company focuses on creating pharmaceutical preparations for diagnosing and treating oncological, tumor, and inflammatory diseases by pursuing novel approaches that target the tumor microenvironment. Its drug development pipeline and clinical biomarker platform aim to create drugs that inhibit extracellular matrix synthesis and stabilization, and silence activated stromal cells through pleiotropic mechanisms.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

GuideSpark, Inc. is a company that specializes in developing employee communication software aimed at enhancing engagement and interaction within organizations. Its primary offering, the GuideSpark Communicate Cloud, allows human resource teams to implement communication campaigns and create multi-format content experiences that facilitate the adoption of various HR programs, including benefits, performance management, and compensation. The platform also features Total Rewards communication journeys, which help employees appreciate their company's investment in total rewards, alongside tools for talent management and promoting company culture and core values. Founded in 2008 and headquartered in Redwood City, California, GuideSpark serves over 1,000 enterprise customers, guiding them through organizational change by fostering employee engagement and behavior modification to achieve critical business goals. The company also has additional offices in Portland, Boston, San Francisco, and New York.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies. The company specializes in creating human immunoglobulin isotype G4 monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, which targets CD73; SRF617, which inhibits CD39; SRF388, aimed at interleukin 27; and SRF813, which targets CD112R. Additionally, Surface Oncology is advancing several preclinical programs that address other critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established strategic collaborations with Novartis Institutes for Biomedical Research and Merck Sharp & Dohme Corp. to advance the development of its therapies, including evaluating the combination of SRF617 with Merck’s KEYTRUDA. Founded in 2014, Surface Oncology aims to leverage novel immunotherapy targets and insights into cancer immuno-biology to enhance anti-tumor immune responses.

ClearMotion, Inc. is an automotive technology company that specializes in developing advanced suspension systems to enhance vehicle comfort and handling. Founded out of MIT in 2008 and based in Billerica, Massachusetts, with operations in Nuneaton, United Kingdom, ClearMotion integrates hardware and software to create a proactive ride system that anticipates and counteracts shocks and vibrations from uneven road surfaces. This innovative technology not only improves ride quality but also enhances the overall user experience in vehicles. By mapping road surfaces in real-time, ClearMotion's system can mitigate the effects of road roughness almost instantaneously, ensuring a smoother ride for both drivers and passengers.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Solace Therapeutics, Inc. is a medical device company based in Framingham, Massachusetts, that specializes in developing non-surgical, office-based treatments for common bladder disorders, including stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction, and lower urinary tract symptoms (LUTS). The company’s flagship product, the Vesair Bladder Control System, is a lightweight device designed to float within the urinary bladder, effectively addressing involuntary urinary leakage without the need for anesthesia or surgical intervention. Solace Therapeutics aims to enhance patients' quality of life by offering a treatment option that minimizes the side effects often associated with traditional drug and surgical therapies, allowing for a reversible and less intrusive approach to bladder health.

Acquia Inc., established in 2007, is a technology company based in Boston, Massachusetts, with an additional office in Pune, India. It specializes in developing and operating a cloud-based platform that empowers organizations to create, manage, and optimize digital experiences. Acquia's platform offers a range of solutions, including commerce, content, community, and contextual services, catering to diverse industries such as government, consumer brands, higher education, and more. Key products include Acquia Cloud, a Platform-as-a-Service for Drupal website creation and management; Acquia Lift for site templating; Acquia Content Hub for multi-channel content distribution; and Acquia Journey for data-driven customer journey creation. Acquia also provides web content management, security, commerce solutions, and technical support services. The company's platform enables organizations to accelerate time to market, enhance customer engagement, and deliver contextually relevant digital experiences across various channels.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

Tamr, Inc. is an enterprise data unification company that specializes in developing solutions for data integration and management. Founded in 2013 by industry veterans, the company offers a platform that combines machine learning with human insight to effectively identify and connect diverse internal and external data sources. This technology allows organizations to curate siloed data at scale, generating valuable insights for various business applications. Tamr's offerings include enterprise data preparation software, clinical data conversion, procurement optimization, and customer data integration, catering to industries such as financial services, life sciences, government, and telecommunications. With its headquarters in Cambridge, Massachusetts, Tamr also maintains offices in major U.S. cities and London, reflecting its commitment to delivering innovative data solutions to a broad range of clients.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Kensho Technologies, Inc. is a provider of advanced analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. The company develops Kensho Financial Analytics Software, which delivers scalable analytical solutions to enhance decision-making within commercial entities. Kensho's offerings also include the Kensho Applied Mind, a sophisticated AI software that enables natural language processing to address complex financial inquiries in plain English. Additionally, Kensho operates a national security division known as Koto. Founded in 2012 and headquartered in Cambridge, Massachusetts, Kensho has expanded its presence with offices in New York, McLean, and Pacific Palisades. As of April 2018, Kensho Technologies operates as a subsidiary of S&P Global Inc.

GuideSpark, Inc. is a company that specializes in developing employee communication software aimed at enhancing engagement and interaction within organizations. Its primary offering, the GuideSpark Communicate Cloud, allows human resource teams to implement communication campaigns and create multi-format content experiences that facilitate the adoption of various HR programs, including benefits, performance management, and compensation. The platform also features Total Rewards communication journeys, which help employees appreciate their company's investment in total rewards, alongside tools for talent management and promoting company culture and core values. Founded in 2008 and headquartered in Redwood City, California, GuideSpark serves over 1,000 enterprise customers, guiding them through organizational change by fostering employee engagement and behavior modification to achieve critical business goals. The company also has additional offices in Portland, Boston, San Francisco, and New York.

Philo is a streaming service that focuses on providing an entertainment-centric experience, offering a wide range of channels, networks, and shows for general media consumption. Inspired by Philo T. Farnsworth, the inventor of electronic television, the company began by targeting the college market and has since evolved into a comprehensive platform for next-generation TV viewing. Headquartered in San Francisco, with additional offices in New York and Cambridge, Massachusetts, Philo allows users to access live streaming of cable channels and major broadcasts. Its features include the ability to pause live channels, enabling viewers to enjoy prime-time television, live news, sports, and entertainment on various devices, including smartphones and computers.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Solace Therapeutics, Inc. is a medical device company based in Framingham, Massachusetts, that specializes in developing non-surgical, office-based treatments for common bladder disorders, including stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction, and lower urinary tract symptoms (LUTS). The company’s flagship product, the Vesair Bladder Control System, is a lightweight device designed to float within the urinary bladder, effectively addressing involuntary urinary leakage without the need for anesthesia or surgical intervention. Solace Therapeutics aims to enhance patients' quality of life by offering a treatment option that minimizes the side effects often associated with traditional drug and surgical therapies, allowing for a reversible and less intrusive approach to bladder health.

Philo is a streaming service that focuses on providing an entertainment-centric experience, offering a wide range of channels, networks, and shows for general media consumption. Inspired by Philo T. Farnsworth, the inventor of electronic television, the company began by targeting the college market and has since evolved into a comprehensive platform for next-generation TV viewing. Headquartered in San Francisco, with additional offices in New York and Cambridge, Massachusetts, Philo allows users to access live streaming of cable channels and major broadcasts. Its features include the ability to pause live channels, enabling viewers to enjoy prime-time television, live news, sports, and entertainment on various devices, including smartphones and computers.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics, catering to global enterprises. Founded in 2011 and headquartered in San Francisco, California, the company offers the SingleStore Managed Service, a cloud database-as-a-service that enables analytics on various cloud platforms, alongside SingleStore DB, a distributed SQL database suitable for both bare metal and hybrid cloud environments. The company focuses on operational analytics and supports modern data platform solutions that encompass IoT analytics, risk management, and customer engagement. SingleStore serves a diverse range of industries, including financial services, media communications, energy and utilities, government, and retail. The company, previously known as MemSQL Inc., rebranded to SingleStore, Inc. in October 2020 and also maintains offices in Seattle, Boston, Portland, Lisbon, and London.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Predictive Biosciences, Inc. is a molecular diagnostics company focused on developing diagnostic products aimed at enhancing cancer management. Founded in 2006 and headquartered in Lexington, Massachusetts, the company specializes in proteomics and oncology, particularly in the area of tumor biomarkers. Predictive Biosciences offers a range of assays that detect urinary biomarkers, which are indicative of the physiological changes associated with cancer development and progression. Among its key products are the Triage Monitoring Assay, which enables physicians to postpone invasive diagnostic procedures, the Interval Monitoring Assay for cancer surveillance between follow-up appointments, and the Stratification Assay to assist physicians in managing patient care decisions.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

Play Hard Sports, Inc. (Play Hard) is the first casual sports network in North America focused exclusively on developing, publishing and distributing exceptional sports games and entertainment across the Internet. Headquartered in the shadow of the world-famous football stadium at Foxboro, Massachusetts, Play Hard is creating the next-generation in online sports with no massive download, no long waiting for the game to load, and no required fees to play. Play Hard provides its audience with high-quality sports titles that can be played almost anywhere and anytime.

Predictive Biosciences, Inc. is a molecular diagnostics company focused on developing diagnostic products aimed at enhancing cancer management. Founded in 2006 and headquartered in Lexington, Massachusetts, the company specializes in proteomics and oncology, particularly in the area of tumor biomarkers. Predictive Biosciences offers a range of assays that detect urinary biomarkers, which are indicative of the physiological changes associated with cancer development and progression. Among its key products are the Triage Monitoring Assay, which enables physicians to postpone invasive diagnostic procedures, the Interval Monitoring Assay for cancer surveillance between follow-up appointments, and the Stratification Assay to assist physicians in managing patient care decisions.

Play Hard Sports, Inc. (Play Hard) is the first casual sports network in North America focused exclusively on developing, publishing and distributing exceptional sports games and entertainment across the Internet. Headquartered in the shadow of the world-famous football stadium at Foxboro, Massachusetts, Play Hard is creating the next-generation in online sports with no massive download, no long waiting for the game to load, and no required fees to play. Play Hard provides its audience with high-quality sports titles that can be played almost anywhere and anytime.

Hydra Biosciences, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative drugs targeting pain, inflammation, and cardiovascular diseases. The company leverages its expertise in novel ion channels and proprietary high-throughput screening platforms to identify and advance drug candidates addressing substantial unmet medical needs. Hydra's focus lies in TRP ion channels, offering potential for selective and safer therapies compared to classical voltage-gated channels. Since its founding, Hydra has secured significant funding from prominent investors such as Abingworth Ventures, Advanced Technology Ventures, and New Enterprise Associates, among others.

Konarka Technologies, Inc. develops and advances nano-enabled polymer photovoltaic materials for commercial, industrial, government, and consumer applications. It provides standard products to serve portable power needs; and custom solutions, such as roll up chargers, personal accessories, and fold up chargers. The company's products are used in outdoor, portable power, indoor and remote sensing, and mission critical applications. It has strategic partnerships with Air Products, 24 Innovations, Kurz, SkyShades, Chevron, Merck, Toppan Forms, Dupont, Siemens, and the U.S. Air Force. Konarka Technologies, Inc. was founded in 2001 and is headquartered in Lowell, Massachusetts with business development offices in Asia. It has a research and development facility in Austria. The company has operations in the United States, Europe, and Asia.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.